Search Results

Canada Supports IAEA "Rays of Hope" Initiative for the First Time, Will Provide Medical Isotope Training for Latin America

The Canadian Nuclear Isotope Council (CNIC) announced on September 10 that Canada has for the first time formally provided support to the International Atomic Energy Agency (IAEA) Rays of Hope initiative, and will help enhance cancer diagnosis and treatment capacity in Latin America through training in the production of medical radioisotopes and radiopharmaceuticals. The Rays of Hope initiative aims to expand access to cancer treatment and radiotherapy infrastructure in low- and middle-income countries. Under the arrangement, from November 8 to 14, 26 relevant sector leaders from Argentina, Brazil, Chile and Mexico will travel to Ontario, Canada, to participate in a training program jointly organized by Bruce Power and McMaster University. The training will focus on medical isotopes...

2026-09-11

Argentina Plans to Commission RA-10 Multipurpose Reactor in 2027

Argentina's National Atomic Energy Commission (CNEA) and the Nuclear Affairs Secretariat recently stated that the RA-10 multipurpose research reactor at the Ezeiza Atomic Centre is planned to begin commissioning before the end of this year, with the goal of achieving operation in 2027. (Image source: CNEA) According to the project site, RA-10 is currently in its final phase, with approximately 530 workers completing the remaining construction and system testing in preparation for subsequent reactor commissioning and operation. The project is currently about 96% complete overall. RA-10 is a 30 MW open-pool multipurpose research reactor that will provide products and services to the medical, scientific, technological, and industrial sectors once completed. Among these, molybdenum-99 will be one of its key products...

2026-09-08

Baiyunshan Xike Visits Jiujiang, Jiangxi to Explore Nuclear Medicine Industry Chain Cooperation

Recently, a delegation from Guangzhou Baiyunshan Xike Health Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Holdings Limited (GP Corp.), visited Jiujiang City, Jiangxi Province, conducting field inspections and discussion exchanges in Ruichang City, Jiujiang Economic Development Zone, and Pengze County, focusing on cooperation across the full nuclear medicine industry chain. Liu Hong, Director of the Scientific Research Project Management Department of GP Corp. and Chairman and General Manager of Baiyunshan Xike, led the core team in exchanges with Chen Shuilian, Member of the Party Leadership Group and Vice Mayor of Jiujiang Municipal People's Government, as well as responsible officials from Ruichang City, Pengze County, and Jiujiang Economic Development Zone, reaching multiple consensuses on subsequent cooperation. The inspection covered key facilities including the Ruichang Institute of Nuclear Physics Applications, the Biomedical (Nuclear) Industrial Park in Jiujiang Economic Development Zone, and the Jiangxi Tianhong Nuclear Technology project site in Pengze County. The delegation conducted in-depth visits to research laboratories, industrial parks, and projects under construction to understand local capabilities in nuclear technology research, isotope R&D infrastructure, project construction progress, as well as land and industrial supporting conditions.

2026-09-07

Ionetix begins routine supply of astatine-211 in North America, expanding sources of isotopes for targeted alpha therapy

Ionetix, a U.S. medical isotope producer, recently announced that it has begun routine supply of astatine-211 (At-211) in North America. The company stated that this development expands the supply sources of At-211 and is expected to support its further application in preclinical research and clinical development. Ionetix noted that it believes it is the first non-academic commercial supplier of At-211 in the United States. Ionetix produces At-211 at its facility in Lansing, Michigan, leveraging its proprietary cyclotron technology. The company currently operates a 30 MeV cyclotron equipped with optimized target technology, aiming to support the production of clinical-grade At-211. The company stated that its production ca...

2026-09-02

Japanese team achieves high-precision mass measurements of argon isotopes, revealing variations in the strength of the new magic number N=32

An international collaborative research team comprising RIKEN and the High Energy Accelerator Research Organization (KEK), among others, conducted high-precision mass measurements of short-lived argon isotopes far from the line of nuclear stability, using the superconducting RI beam generation and separation device BigRIPS at the RI Beam Factory (RIBF) of RIKEN Nishina Center for Accelerator-Based Science, as well as the CRISMASS system, a stationary slow radioactive isotope precision mass spectrometer jointly developed by the two institutions. The research team directly measured the mass of argon-50 (^50Ar, 18 protons, 32 neutrons) for the first time, and improved the mass measurement precision of argon-49 (^49Ar) by approximately 250-fold compared to previous measurements, providing insights into the energy of the two-neutron shell gap near the new magic number N=32. The results have been...

2026-08-31

China Isotope & Radiation Plans to Invest RMB 400 Million in Zhejiang Nuclear Technology Application Industry Fund

China Isotope & Radiation Corporation announced on August 28 that its board of directors has approved entering into a partnership agreement with CNNC, CNNC Capital, CNNC Fund, National Industry Investment Fund, Zhejiang Venture Capital Guidance Fund, Jiaxing Changchuang Industrial Investment, and Haiyan County State-owned Capital Investment to jointly establish CNNC (Zhejiang) Nuclear Technology Application Industry Investment Fund Partnership (Limited Partnership). According to the announcement, the fund will be registered in Jiaxing City, Zhejiang Province, with partners intending to subscribe to a total capital contribution of RMB 3 billion. Among them, China Isotope & Radiation plans to contribute RMB 400 million from internal resources, accounting for 13.33% of the fund's total subscribed capital; CNNC Fund, as the general partner, plans to contribute RMB 30 million, accounting for 1%; the National...

2026-08-29

U.S. Marathon Fusion Demonstrates Hydrogen and Lithium Isotope Enrichment Technology

U.S.-based Marathon Fusion announced on August 27 that it has successfully demonstrated hydrogen and lithium isotope enrichment technology using its proprietary plasma centrifuge. The company stated that this advancement addresses the fuel cycle needs of fusion energy and related isotope supply requirements. In the deuterium-tritium fusion pathway, hydrogen isotope processing is critical to the continuous operation of fusion devices, while lithium isotope enrichment is closely tied to tritium production. The U.S. Department of Energy (DOE) released its "Fusion Science and Technology Roadmap" in June of this year, which identifies tritium processing as one of the core challenges, noting that related progress is essential for achieving sustained deuterium-tritium fusion operation and validating fusion as a large-scale energy form...

2026-08-28

Bruce Power Aims to Generate Over CAD 13.3 Billion in Economic Impact in Canada Over Next 18 Months

Bruce Power recently stated that over the next 18 months, the company expects to generate more than CAD 13.3 billion in economic impact across Canada, with related investments primarily stemming from its nuclear plant operations and life extension programs, supporting businesses and jobs in Ontario and other regions of Canada. Bruce Power stated that since launching the "Canada First" program in 2025, the company has invested over CAD 6.6 billion in Canada between January 2025 and June 2026, and plans to invest an additional CAD 7.7 billion by the end of 2027. The company noted that its spending within Canada accounts for more than 95% of total expenditures. As a nuclear operator located in Bruce County, Ontario...

2026-08-28

Rare Germanium Isotope Infrared Spectral Signatures Elucidated in Detail for the First Time

The press service of the Russian Ministry of Education and Science reported on August 25 that scientists from Tomsk Polytechnic University, in collaboration with an international research team, have for the first time conducted a detailed study of the infrared spectra of two rare germanium isotopes and identified characteristic spectral signatures that can be used to recognize the relevant isotopes in complex gas mixtures. The research team selected two highly enriched isotopes—germanium-72 and germanium-73—as the subjects of the study, recording their spectral information using a high-resolution Fourier transform spectrometer. This instrument is capable of resolving closely spaced spectral lines, providing the conditions for analyzing subtle spectral changes induced by isotopic substitution. The researchers stated that precise spectral data for different germanium isotopes remain relatively scarce in the scientific literature, and such data are of significant importance for identifying molecules in planetary atmospheres and for producing ultra-pure germanium isotopes for quantum technologies and modern electronics.

2026-08-26

South Korea Clarifies Statutory Functions of KAERI Radiation Injury Treatment Hospital

The Korea Atomic Energy Research Institute (KAERI) announced on August 24 that the National Assembly had passed a partial amendment to the Act on the Promotion of Radiation and Radioisotope Utilization at its plenary session on August 20, incorporating the functions of a radiation injury treatment hospital, along with supporting research and technology development, into the institute's statutory scope of business. Under the amendment, relevant institutions will provide specialized medical services to individuals who have sustained radiation injuries or are at risk of such injuries. Radiation injury generally refers to health abnormalities in the human body resulting from excessive exposure to radiation. Such injuries may not manifest immediately after exposure; even when early symptoms appear only as skin redness, they can later progress to ulceration, necrosis, and affect the blood or bone marrow systems. Some individuals also require long-term follow-up to monitor for delayed health risks such as cancer.

2026-08-24

Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project Officially Launched

On August 22, the groundbreaking ceremony for the Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project was held in Hengyang, Hunan Province. Officials from Hengyang City and Zhuhui District, representatives from relevant colleges of the University of South China, investment institutions, and relevant personnel from New Radiopharmaceutical Medical attended the event. Cai Jiming, Chairman and President of New Radiopharmaceutical Medical, stated at the ceremony that the project's landing in Hengyang represents an important strategic layout for the company's nuclear medicine business. From contract signing to construction commencement, the project has received support from local governments, partners, and relevant organizations. The company will leverage this project as an opportunity to continue advancing the transformation of innovative achievements in the fields of medical isotopes and radiopharmaceuticals. Wang Jing, Deputy Mayor of Hengyang City, stated that Hengyang...

2026-08-22

Research reactors provide critical support for global medical, scientific, and industrial innovation

The International Atomic Energy Agency recently reported that research reactors continue to play a vital role in medical, scientific, industrial innovation, and nuclear workforce development, serving as key infrastructure for many countries to build their nuclear science and technology capabilities. Currently, 228 research reactors are in operation across 54 countries worldwide, with another 23 under construction or in the planning stage. Unlike nuclear power reactors used for electricity generation, research reactors primarily produce neutrons for applications in medicine, industry, agriculture, geological sciences, forensics, and other fields. With capabilities such as neutron irradiation, neutron imaging, elemental analysis, and radioisotope production, research reactors have become important platforms for advancing peaceful nuclear technology applications. In the medical field, research...

2026-08-23

Full-Life Technologies Completes Construction of Belgian Radiopharmaceutical Production Facility and Initiates Accelerator Commissioning

Full-Life Technologies (hereinafter referred to as "Full-Life"), a privately held, fully integrated, clinical-stage international radiopharmaceutical therapy company, announced on August 20 that its radiopharmaceutical production facility in Gembloux, Belgium, has completed construction and received authorization to commence accelerator commissioning and enter the initial ramp-up phase. (Full-Life Technologies Belgium Radiopharmaceutical Production Facility) This milestone marks a significant step forward in Full-Life's vertically integrated radioisotope production capabilities moving toward formal operational status. With the completion of facility construction, the company has entered the next phase of operational preparation, including accelerator installation, phased commissioning, and validation of critical safety and operational systems.

2026-08-20

Norway's Thor Medical AlphaOne High-Purity Alpha Radioisotope Facility to Be Officially Inaugurated

Thor Medical ASA announced on August 19 that its AlphaOne production facility at the Herøya industrial park in Norway will be officially inaugurated on September 9, 2026, with Norwegian Prime Minister Jonas Gahr Støre attending the ceremony. According to reports, AlphaOne is Thor Medical's first industrial-scale production facility for high-purity α radioisotopes and the first of its kind globally. The facility is already in operation, primarily producing isotope products for next-generation targeted cancer therapies, supplying high-purity α emitters to the radiopharmaceutical industry. Thor Medical CEO Jasper Kurth stated that AlphaOn...

2026-08-19

ASP Isotopes Subsidiary Evaluates Metal Hydrofluorination and Fluorination Project in Namibia

ASP Isotopes Inc. recently announced that its wholly-owned subsidiary, Quantum Leap Energy LLC, is evaluating metal conversion opportunities in Namibia, with work focusing on technologies and processes required for critical stages of the fission and fusion nuclear fuel cycles. According to the disclosure, the evaluation includes plans to construct a pilot-scale hydrofluorination and fluorination facility in the Walvis Bay area of Namibia. Public environmental and social impact assessments and consultation procedures for the project have already been initiated. The proposed facility will be used to develop, test, and demonstrate metal hydrofluorination and fluorination processes. In accordance with Namibian regulatory requirements, relevant public consultation notices have been published through customary local channels. The company...

2026-08-19